Histone Deacetylase Inhibitors
Market: Overview
Histone deacetylase inhibitors (HDIs,
HDAC inhibitors, HDACi) are chemical compounds that interfere with and inhibit
histone deacetylases. Histone deacetylases inhibitors are a new class of
anti-cancer agents. HDACs play an important role in non-epigenetic and
epigenetic regulations including apoptosis, cell cycle, and death apoptosis.
Histone deacetylase inhibitors are emerging compounds with potential
application in prognosis, treatment, and diagnosis of cancer. Histone
deacetylase inhibitors accumulate acetylated nuclear histone in normal tissues
and tumors. Hence, the inhibition results in acetylation transcription factors
including estrogen receptor-alpha, p53, and GATA-1. These enzymes are found in
plants, animals, bacteria, and fungi. There are about 18 known human HDACs,
which are classified into four classes based on their structures. Class I
includes histone deacetylase 1, histone deacetylase 2, histone deacetylase 3,
and histone deacetylase 8. Class II includes histone deacetylase 4, histone
deacetylase 5, histone deacetylase 7, and histone deacetylase 9. Class III
includes histone deacetylase 6 and histone deacetylase 10, whereas class
IV includes histone deacetylase 11.
Request Brochure –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1927
Histone Deacetylase
Inhibitors Market: Key Trends
The global histone deacetylase
inhibitors market is projected to grow at a rapid pace during the forecast period.
Rise in prevalence of cancer across the globe resulting in the increase in the
need for improved and effective therapies is a major factor anticipated to
drive the global histone deacetylase inhibitors market during the forecast
period. According to the World Health Organization, cancer is the second major
cause of death globally. Cancer accounted for an estimated 9.6 million deaths
in 2018. Globally, about 1 in 6 deaths occurs due to cancer and about 70% of
deaths occur in low and middle income countries. Additionally, increase in
collaboration among histone deacetylase inhibitors manufacturers and research
& development on treatment of cancer and other chronic diseases are
expected to propel the global histone deacetylase inhibitors market. However,
uncertainty issues and inadequate reimbursement for histone deacetylase
inhibitors are likely to restrain the global market during the forecast period.
Request
COVID Analysis on Histone Deacetylase Inhibitors Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1927
Histone Deacetylase
Inhibitors Market: Segmentation
The global histone deacetylase
inhibitors market can be segmented based on class, application and end-user. In
terms of class, the market can be classified into class I HDACs, class II
HDACs, class III HDACs, and class IV HDACs. Based on application, the global
histone deacetylase inhibitors market can be categorized into neurology,
oncology, and others. Oncology is expected to be a major segment of the market
due to large patient population and increase in the need for newer therapies to
treat cancer. FDA-approved products currently available in the market include
Vidaza, orinostat (Zolinza), Dacogen, and Romidepsin (Istodax). However,
pharmaceutical companies are investing in R&D and pre-clinical activities
of histone deacetylase inhibitors for treatment of different diseases. In terms
of end-user, the market can be divided into hospitals, specialty clinics, and
research & academic institutes.
Request customization on Histone Deacetylase Inhibitors Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1927
Histone Deacetylase
Inhibitors Market: Regional Analysis
Based on region, the global histone
deacetylase inhibitors market can be segmented into North America, Asia
Pacific, Europe, Latin America, and Middle East & Africa. North America is
projected to lead the global market during the forecast period, followed by Europe.
Dominance of the two regions is attributed to high income of the population,
high R&D spending capacity, early adoption of innovative therapeutics, and
well-established health care infrastructure. Asia Pacific is expected to be the
fastest growing market owing to improved health care infrastructure, increase
in cancer patient population, and rise in government initiatives.
Pre Book Histone Deacetylase Inhibitors Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=1927<ype=S
Histone Deacetylase
Inhibitors Market: Competitive Landscape
Key players operating in the global
histone deacetylase inhibitors market include Celleron Therapeutics Ltd.,
Novartis International AG, Pfizer, Inc., Celgene Corporation, Eisai Co., Ltd.,
Merck & Co., AstraZeneca plc, Acetylon Pharmaceuticals, Inc., and Envivo
Pharmaceuticals.
About Us
Transparency Market Research is a global market intelligence company,
providing global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides forward-looking
insight for thousands of decision makers. Our experienced team of analysts,
researchers, and consultants, uses proprietary data sources and various tools
and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and information.
With a broad research and analysis capability, Transparency Market Research
employs rigorous primary and secondary research techniques in developing
distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
